Temat: "Anti-HIV Agents" - OpacWWW

Skocz do pozycji: 1 1.

Tytuł :: Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Autorzy :: Overton ET; University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: .
Richmond G; Nova Southeastern University, FL, USA.
Rizzardini G; Fatebenefratelli Sacco Hospital, Milan, Italy; School of Clinical Medicine, Faculty of Health Science, University of the Witwatersrand, Johannesburg, South Africa.
Jaeger H; MVZ Karlsplatz, HIV Research and Clinical Care Centre, Munich, Germany.
Orrell C; Desmond Tutu HIV Foundation, University of Cape Town Medical School, Cape Town, South Africa.
Nagimova F; Republic Center for the Prevention and Control of AIDS and Infectious Diseases, Russia.
Bredeek F; Metropolis Medical, San Francisco, CA, USA.
García Deltoro M; General Hospital of Valencia, Valencia, Spain.
Swindells S; University of Nebraska Medical Center, Omaha, USA.
Andrade-Villanueva JF; Hospital Civil 'Fray Antonio Alcalde', Guadalajara, Mexico.
Wong A; Department of Medicine, University of Saskatchewan, Regina, Saskatchewan, Canada.
Khuong-Josses MA; CH - Hôpital Delafontaine, Saint-Denis, France.
Van Solingen-Ristea R; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
van Eygen V; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Crauwels H; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Ford S; GlaxoSmithKline, Research Triangle Park, NC, USA.
Talarico C; ViiV Healthcare, Research Triangle Park, NC, USA.
Benn P; ViiV Healthcare, Brentford, UK.
Wang Y; GlaxoSmithKline, Collegeville, PA, USA.
Hudson KJ; ViiV Healthcare, Research Triangle Park, NC, USA.
Chounta V; ViiV Healthcare, Brentford, UK.
Cutrell A; ViiV Healthcare, Research Triangle Park, NC, USA.
Patel P; ViiV Healthcare, Research Triangle Park, NC, USA.
Shaefer M; ViiV Healthcare, Research Triangle Park, NC, USA.
Margolis DA; ViiV Healthcare, Research Triangle Park, NC, USA.
Smith KY; ViiV Healthcare, Research Triangle Park, NC, USA.
Vanveggel S; Janssen Research and Development, Janssen Pharmaceutica NV, Beerse, Belgium.
Spreen W; ViiV Healthcare, Research Triangle Park, NC, USA.; Pokaż więcej
Źródło :: Lancet (London, England) [Lancet] 2021 Dec 19; Vol. 396 (10267), pp. 1994-2005. Date of Electronic Publication: 2020 Dec 09.
Typ publikacji :: Clinical Trial, Phase III; Equivalence Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms :: HIV-1*
Anti-HIV Agents/*administration & dosage
HIV Infections/*drug therapy
Pyridones/*administration & dosage
Rilpivirine/*administration & dosage
Adult ; Alanine Transaminase/blood ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/blood ; Delayed-Action Preparations ; Drug Administration Schedule ; Drug Therapy, Combination ; Female ; Humans ; Injections, Intramuscular ; Male ; Middle Aged ; Pyridones/adverse effects ; Pyridones/blood ; RNA, Viral/blood ; Rilpivirine/adverse effects ; Rilpivirine/blood ; Viral Load
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 2 2.

Tytuł :: Lead optimization to improve the antiviral potency of 2-aminobenzamide derivatives targeting HIV-1 Vif-A3G axis.
Autorzy :: Zhong X; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China.
Luo R; Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology,Chinese Academy of Sciences, Kunming, Yunnan, 650223, PR China.
Yan G; School of Pharmacy, Henan University, Kaifeng, Henan, 475001, PR China.
Ran K; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China.
Shan H; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China.
Yang J; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China.
Liu Y; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China.
Yu S; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China.
Pu C; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China.
Zheng Y; Key Laboratory of Animal Models and Human Disease Mechanisms of Chinese Academy of Sciences & Yunnan Province, Kunming Institute of Zoology,Chinese Academy of Sciences, Kunming, Yunnan, 650223, PR China. Electronic address: .
Li R; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, 610041, PR China. Electronic address: .; Pokaż więcej
Źródło :: European journal of medicinal chemistry [Eur J Med Chem] 2021 Nov 15; Vol. 224, pp. 113680. Date of Electronic Publication: 2021 Jul 01.
Typ publikacji :: Journal Article
MeSH Terms :: APOBEC-3G Deaminase/*metabolism
Anti-HIV Agents/*chemistry
HIV-1/*metabolism
ortho-Aminobenzoates/*chemistry
vif Gene Products, Human Immunodeficiency Virus/*antagonists & inhibitors
Anti-HIV Agents/metabolism ; Anti-HIV Agents/pharmacology ; Binding Sites ; Cell Line ; Cell Survival/drug effects ; Drug Design ; Drug Resistance, Viral/drug effects ; HIV-1/drug effects ; Humans ; Molecular Docking Simulation ; Structure-Activity Relationship ; ortho-Aminobenzoates/metabolism ; ortho-Aminobenzoates/pharmacology ; vif Gene Products, Human Immunodeficiency Virus/metabolism
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 3 3.

Tytuł :: Survey of pretreatment HIV drug resistance and the genetic transmission networks among HIV-positive individuals in southwestern China, 2014-2020.
Autorzy :: Xu X; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Luo L; Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, 530028, China.
Song C; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Li J; Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, 530028, China.
Chen H; Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, 530028, China.
Zhu Q; Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, 530028, China.
Lan G; Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, 530028, China.
Liang S; Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, 530028, China.
Shen Z; Guangxi Key Laboratory of Major Infectious Disease Prevention Control and Biosafety Emergency Response, Guangxi Center for Disease Control and Prevention, Nanning, 530028, China.
Cao Z; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Feng Y; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Liao L; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Xing H; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Shao Y; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China.
Ruan Y; National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, 102206, China. .; Pokaż więcej
Źródło :: BMC infectious diseases [BMC Infect Dis] 2021 Nov 12; Vol. 21 (1), pp. 1153. Date of Electronic Publication: 2021 Nov 12.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
China/epidemiology ; Cross-Sectional Studies ; Drug Resistance, Viral/genetics ; Genotype ; Humans ; Mutation ; Prevalence
: Czasopismo naukowe

Szczegóły Pełny tekst

Skocz do pozycji: 4 4.

Tytuł :: HIV-1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial.
Autorzy :: Parikh UM; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Penrose KJ; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Heaps AL; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Halvas EK; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Goetz BJ; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Gordon KC; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Hardesty R; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Sethi R; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Schwarzmann W; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Szydlo DW; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Husnik MJ; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Chandran U; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Palanee-Phillips T; Wits Reproductive Health and HIV Institute, Johannesburg, South Africa.
Baeten JM; Departments of Global Health, Medicine, Epidemiology, University of Washington, Seattle, Washington, USA.
Mellors JW; Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Pokaż więcej
Corporate Authors :: MTN-020 Study Team
Źródło :: Journal of the International AIDS Society [J Int AIDS Soc] 2021 Nov; Vol. 24 (11), pp. e25833.
Typ publikacji :: Clinical Trial, Phase III; Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Seropositivity*/drug therapy
HIV-1*/genetics
Drug Resistance, Viral/genetics ; HIV Reverse Transcriptase/genetics ; HIV Reverse Transcriptase/pharmacology ; HIV Reverse Transcriptase/therapeutic use ; Humans ; Mutation ; Pyrimidines ; Reverse Transcriptase Inhibitors/therapeutic use
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 5 5.

Tytuł :: Comparative safety review of recommended, first-line single-tablet regimens in patients with HIV.
Autorzy :: Ciccullo A; Gemelli Molise Hospital, Campobasso, Italia.
Baldin G; Mater Olbia Hospital, Olbia, Italia.; UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia.
Putaggio C; Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Università Cattolica Del Sacro Cuore, Roma, Italy.
Di Giambenedetto S; UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia.; Dipartimento di Sicurezza e Bioetica Sezione Malattie Infettive, Università Cattolica Del Sacro Cuore, Roma, Italy.
Borghetti A; UOC Malattie Infettive, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma, Italia.; Pokaż więcej
Źródło :: Expert opinion on drug safety [Expert Opin Drug Saf] 2021 Nov; Vol. 20 (11), pp. 1317-1332. Date of Electronic Publication: 2021 May 27.
Typ publikacji :: Comparative Study; Journal Article; Review
MeSH Terms :: Anti-HIV Agents/*administration & dosage
HIV Infections/*drug therapy
Reverse Transcriptase Inhibitors/*administration & dosage
Animals ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/pharmacology ; Drug Combinations ; HIV Infections/virology ; Humans ; Reverse Transcriptase Inhibitors/adverse effects ; Reverse Transcriptase Inhibitors/pharmacology ; Tablets
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 6 6.

Tytuł :: Acquired HIV drug resistance and virologic monitoring in a HIV hyper-endemic setting in KwaZulu-Natal Province, South Africa.
Autorzy :: Chimukangara B; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. .; Department of Virology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa. .; Critical Care Medicine Department, NIH Clinical Center, Bethesda, MD, USA. .
Lessells RJ; KwaZulu-Natal Research and Innovation Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Doris Duke Medical Research Institute, Durban, South Africa.
Singh L; KwaZulu-Natal Research and Innovation Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Doris Duke Medical Research Institute, Durban, South Africa.
Grigalionyte I; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Yende-Zuma N; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.; South African Medical Research Council (SAMRC), CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Adams R; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Dawood H; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.; Infectious Diseases, Department of Medicine, Greys Hospital, Durban, South Africa.
Dlamini L; National Department of Health, Pretoria, South Africa.
Buthelezi S; East Boom Community Health Centre, Pietermaritzburg, South Africa.
Chetty S; East Boom Community Health Centre, Pietermaritzburg, South Africa.
Diallo K; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa.
Duffus WA; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa.
Mogashoa M; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa.
Hagen MB; Division of Global HIV and Tuberculosis, Center for Global Health, Centers for Disease Control and Prevention, Pretoria, South Africa.
Giandhari J; KwaZulu-Natal Research and Innovation Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Doris Duke Medical Research Institute, Durban, South Africa.
de Oliveira T; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.; KwaZulu-Natal Research and Innovation Platform (KRISP), College of Health Sciences, University of KwaZulu-Natal, Doris Duke Medical Research Institute, Durban, South Africa.
Moodley P; Department of Virology, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal and National Health Laboratory Service, Durban, South Africa.
Padayatchi N; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
Naidoo K; Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.; South African Medical Research Council (SAMRC), CAPRISA HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.; Pokaż więcej
Źródło :: AIDS research and therapy [AIDS Res Ther] 2021 Oct 16; Vol. 18 (1), pp. 74. Date of Electronic Publication: 2021 Oct 16.
Typ publikacji :: Journal Article; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
Adult ; Cross-Sectional Studies ; Drug Resistance ; Drug Resistance, Viral/genetics ; Humans ; Lamivudine/therapeutic use ; South Africa/epidemiology
: Czasopismo naukowe

Szczegóły Pełny tekst Pełny tekst

Skocz do pozycji: 7 7.

Tytuł :: Drug Resistance Mutations Among South African Children Living With HIV on WHO-recommended ART Regimens.
Autorzy :: Hackett S; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Teasdale CA; Department of Epidemiology and Biostatistics, CUNY Graduate School of Public Health & Health Policy, New York, USA.; ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York, USA.; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.
Pals S; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Muttiti A; ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York, USA.
Mogashoa M; US Centers for Disease Control and Prevention, Pretoria, South Africa.
Chang J; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Zeh C; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Ramos A; US Centers for Disease Control and Prevention, Maputo, Mozambique.
Rivadeneira ED; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
DeVos J; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Sleeman K; US Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abrams EJ; ICAP at Columbia University, Mailman School of Public Health, Columbia University, New York, New York, USA.; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York, USA.; Department of Pediatrics, Vagelos College of Physicians & Surgeons, Columbia University, New York, New York, USA.; Pokaż więcej
Źródło :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Oct 05; Vol. 73 (7), pp. e2217-e2225.
Typ publikacji :: Journal Article; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
MeSH Terms :: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
Drug Resistance, Viral*
HIV Infections*/drug therapy
HIV-1*/drug effects
HIV-1*/genetics
Female ; Humans ; Infectious Disease Transmission, Vertical ; Mutation ; World Health Organization
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 8 8.

Tytuł :: Pretreatment and Acquired Antiretroviral Drug Resistance Among Persons Living With HIV in Four African Countries.
Autorzy :: Crowell TA; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Danboise B; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Parikh A; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Esber A; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Dear N; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Coakley P; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Kasembeli A; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; HJF Medical Research International, Kericho, Kenya.
Maswai J; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; HJF Medical Research International, Kericho, Kenya.
Khamadi S; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; HJF Medical Research International, Mbeya, Tanzania.
Bahemana E; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; HJF Medical Research International, Mbeya, Tanzania.
Iroezindu M; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; HJF Medical Research International, Abuja, Nigeria.
Kiweewa F; Makerere University Walter Reed Project, Kampala, Uganda.
Owuoth J; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; HJF Medical Research International, Kisumu, Kenya.
Freeman J; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Jagodzinski LL; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Malia JA; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Eller LA; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Tovanabutra S; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.
Peel SA; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Ake JA; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
Polyak CS; US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, USA.; Pokaż więcej
Corporate Authors :: AFRICOS Study Group
Źródło :: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2021 Oct 05; Vol. 73 (7), pp. e2311-e2322.
Typ publikacji :: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
HIV-1*/genetics
Adult ; Cohort Studies ; Drug Resistance, Viral/genetics ; Humans ; Mutation ; Uganda ; Viral Load
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 9 9.

Tytuł :: Pretreatment HIV Drug Resistance Among Adults Initiating or Re-Initiating First-Line Antiretroviral Therapy in Zimbabwe: Fast-Tracking the Transition to Dolutegravir-Based First-Line Regimens?
Autorzy :: Kouamou V; Department of Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Mavetera J; Department of Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Manasa J; Department of Medical Microbiology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Ndhlovu CE; Department of Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Katzenstein D; Department of Molecular Biology, Biomedical Research and Training Institute, Harare, Zimbabwe.
McGregor AM; Department of Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.; Pokaż więcej
Źródło :: AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2021 Oct; Vol. 37 (10), pp. 776-783. Date of Electronic Publication: 2021 Feb 05.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
HIV-1*/genetics
Adult ; Drug Resistance, Viral ; Heterocyclic Compounds, 3-Ring ; Humans ; Oxazines ; Piperazines ; Pyridones ; Viral Load ; Zimbabwe/epidemiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 10 10.

Tytuł :: Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial.
Autorzy :: Matthews RP; Merck & Co., Inc., Kenilworth, NJ, USA. .
Patel M; Merck & Co., Inc., Kenilworth, NJ, USA.
Barrett SE; Merck & Co., Inc., Kenilworth, NJ, USA.
Haspeslagh L; MSD Belgium, Brussels, Belgium.
Reynders T; MSD Belgium, Brussels, Belgium.
Zhang S; Merck & Co., Inc., Kenilworth, NJ, USA.
Rottey S; Ghent University Hospital, Ghent, Belgium.
Goodey A; Merck & Co., Inc., Kenilworth, NJ, USA.
Vargo RC; Merck & Co., Inc., Kenilworth, NJ, USA.
Grobler JA; Merck & Co., Inc., Kenilworth, NJ, USA.
Stoch SA; Merck & Co., Inc., Kenilworth, NJ, USA.
Iwamoto M; Merck & Co., Inc., Kenilworth, NJ, USA.; Pokaż więcej
Źródło :: Nature medicine [Nat Med] 2021 Oct; Vol. 27 (10), pp. 1712-1717. Date of Electronic Publication: 2021 Oct 04.
Typ publikacji :: Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :: Anti-HIV Agents/*administration & dosage
Deoxyadenosines/*administration & dosage
HIV Infections/*drug therapy
Reverse Transcriptase Inhibitors/*administration & dosage
Adult ; Anti-HIV Agents/adverse effects ; Anti-HIV Agents/pharmacokinetics ; Deoxyadenosines/adverse effects ; Deoxyadenosines/pharmacokinetics ; Double-Blind Method ; HIV Infections/genetics ; HIV Infections/virology ; HIV Reverse Transcriptase/antagonists & inhibitors ; HIV-1/drug effects ; HIV-1/pathogenicity ; Humans ; Leukocytes, Mononuclear/drug effects ; Male ; Middle Aged ; Placebos ; Reverse Transcriptase Inhibitors/adverse effects ; Reverse Transcriptase Inhibitors/pharmacokinetics ; Virus Replication/drug effects
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 11 11.

Tytuł :: Short Communication: Prevalence of Transmitted Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors in European and North American Countries Over 20 Years: An Updated Meta-Analysis.
Autorzy :: Snedecor SJ; Pharmerit-an OPEN Health Company, Bethesda, Maryland, USA.; Pokaż więcej
Źródło :: AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2021 Oct; Vol. 37 (10), pp. 751-753. Date of Electronic Publication: 2021 Jul 15.
Typ publikacji :: Journal Article; Meta-Analysis
MeSH Terms :: Anti-HIV Agents*/pharmacology
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
HIV-1*/genetics
Canada/epidemiology ; Drug Resistance, Viral ; Humans ; North America/epidemiology ; Prevalence ; Reverse Transcriptase Inhibitors/pharmacology ; Reverse Transcriptase Inhibitors/therapeutic use ; United States/epidemiology
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 12 12.

Tytuł :: Short Communication: Higher Tenofovir Concentrations in Hair Are Associated with Decreases in Viral Load and Not Self-Reported Adherence in HIV-Infected Adolescents with Second-Line Virological Treatment Failure.
Autorzy :: Chawana T; Department of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Nhachi C; Department of Clinical Pharmacology, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Nathoo K; Department of Paediatrics, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Ngara B; Department of Community Medicine, College of Health Sciences, University of Zimbabwe, Harare, Zimbabwe.
Okochi H; Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Louie A; Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Kuncze K; Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.
Katzenstein D; Department of Medicine, Division of Infectious Diseases, Stanford University, Stanford, California, USA.
Metcalfe J; Department of Medicine, Division of Pulmonary and Critical Care, University of California San Francisco, San Francisco, California, USA.
Gandhi M; Department of Medicine, Division of HIV, Infectious Diseases, and Global Medicine, University of California San Francisco, San Francisco, California, USA.; Pokaż więcej
Źródło :: AIDS research and human retroviruses [AIDS Res Hum Retroviruses] 2021 Oct; Vol. 37 (10), pp. 748-750. Date of Electronic Publication: 2021 Feb 24.
Typ publikacji :: Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
MeSH Terms :: Anti-HIV Agents*/analysis
Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
Tenofovir*/analysis
Tenofovir*/therapeutic use
Viral Load*
Hair/*chemistry
Adolescent ; Female ; Humans ; Male ; Medication Adherence ; Self Report ; Treatment Failure ; Zimbabwe
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 13 13.

Tytuł :: Social Media & PrEP: A Systematic Review of Social Media Campaigns to Increase PrEP Awareness & Uptake Among Young Black and Latinx MSM and Women.
Autorzy :: Kudrati SZ; Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave, NW, Suite 300, Washington, DC, 20052, USA.
Hayashi K; Department of Health Behavior, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Taggart T; Department of Prevention and Community Health, Milken Institute School of Public Health, George Washington University, 950 New Hampshire Ave, NW, Suite 300, Washington, DC, 20052, USA. .; Department of Social and Behavioral Sciences, Yale School of Public Health, New Haven, CT, USA. .; Pokaż więcej
Źródło :: AIDS and behavior [AIDS Behav] 2021 Dec; Vol. 25 (12), pp. 4225-4234. Date of Electronic Publication: 2021 May 03.
Typ publikacji :: Journal Article; Review; Systematic Review
MeSH Terms :: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*
Sexual and Gender Minorities*
Social Media*
Adolescent ; Female ; Homosexuality, Male ; Humans ; Male
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 14 14.

Tytuł :: Transgender Women's Barriers, Facilitators, and Preferences on Tailored Injection Delivery Strategies to Administer Long-Acting Injectable Cabotegravir (CAB-LA) for HIV Pre-exposure Prophylaxis (PrEP).
Autorzy :: Rael CT; University of Colorado College of Nursing, Aurora, CO, USA. .; Program for the Study of LGBT Health at NYSPI/Columbia University and with the Columbia University School of Nursing, New York, NY, USA. .
Lopez-Ríos J; HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute (NYSPI) and Columbia University, New York, NY, USA.
McKenna SA; Consultant at Stacey McKenna, LLC, Fort Collins, CO, USA.
Das D; University of California-Berkeley, San Francisco, CA, USA.
Dolezal C; HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute (NYSPI) and Columbia University, New York, NY, USA.
Abascal E; HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute (NYSPI) and Columbia University, New York, NY, USA.; Columbia University School of Nursing, New York, NY, USA.
Carballo-Diéguez A; HIV Center for Clinical and Behavioral Studies at the New York State Psychiatric Institute (NYSPI) and Columbia University, New York, NY, USA.
Schnall R; Columbia University School of Nursing, New York, NY, USA.
Hope TJ; Northwestern University Feinberg School of Medicine, Evanston, IL, USA.
Bauermeister J; University of Pennsylvania School of Nursing, Philadelphia, PA, USA.
Bockting W; Program for the Study of LGBT Health at NYSPI/Columbia University and with the Columbia University School of Nursing, New York, NY, USA.; Columbia University School of Nursing, New York, NY, USA.; Pokaż więcej
Źródło :: AIDS and behavior [AIDS Behav] 2021 Dec; Vol. 25 (12), pp. 4180-4192. Date of Electronic Publication: 2021 Jul 03.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*
Transgender Persons*
Female ; Humans ; Pyridones
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 15 15.

Tytuł :: Outcomes of Implementing in the Real World the Women's Health CoOp Intervention in Cape Town, South Africa.
Autorzy :: Wechsberg WM; Substance Use, Gender, and Applied Research Program, RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, 27709-2194, USA. .; Maternal and Child Health, University of North Carolina Gillings School of Global Public Health, 135 Dauer Drive, Chapel Hill, NC, 27599, USA. .; Department of Psychology, North Carolina State University, 640 Poe Hall, Campus, Box 7650, Raleigh, NC, 27695, USA. .; Psychiatry and Behavioral Sciences, Duke University School of Medicine, 40 Duke Medicine Circle, Durham, NC, 27710, USA. .
Browne FA; Substance Use, Gender, and Applied Research Program, RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, 27709-2194, USA.; Health Behavior, University of North Carolina Gillings School of Global Public Health, 135 Dauer Drive, Chapel Hill, NC, 27599, USA.
Ndirangu J; Substance Use, Gender, and Applied Research Program, RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, 27709-2194, USA.
Bonner CP; Substance Use, Gender, and Applied Research Program, RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, 27709-2194, USA.
Kline TL; Division for Statistical and Data Sciences, RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, 27709, USA.
Gichane M; Substance Use, Gender, and Applied Research Program, RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, 27709-2194, USA.
Zule WA; Substance Use, Gender, and Applied Research Program, RTI International, 3040 E. Cornwallis Road, Research Triangle Park, NC, 27709-2194, USA.; Pokaż więcej
Źródło :: AIDS and behavior [AIDS Behav] 2021 Dec; Vol. 25 (Suppl 3), pp. 276-289. Date of Electronic Publication: 2021 Apr 23.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/epidemiology
HIV Infections*/prevention & control
Alcohol Drinking/epidemiology ; Alcohol Drinking/prevention & control ; Ethanol ; Female ; Humans ; South Africa/epidemiology ; Women's Health
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 16 16.

Tytuł :: "I had Made the Decision, and No One was Going to Stop Me" -Facilitators of PrEP Adherence During Pregnancy and Postpartum in Cape Town, South Africa.
Autorzy :: Joseph Davey DL; Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, 615 E Charles Young Drive S, Los Angeles, CA, 90095, USA. .; Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa. .
Knight L; Division of Social and Behavioural Sciences, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.; School of Public Health, University of the Western Cape, Bellville, South Africa.
Markt-Maloney J; Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, 615 E Charles Young Drive S, Los Angeles, CA, 90095, USA.
Tsawe N; Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Gomba Y; Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Mashele N; Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.
Dovel K; Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Gorbach P; Department of Epidemiology, Fielding School of Public Health, University of California Los Angeles, 615 E Charles Young Drive S, Los Angeles, CA, 90095, USA.
Bekker LG; The Desmond Tutu Health Foundation, University of Cape Town, Cape Town, South Africa.
Coates TJ; Division of Infectious Diseases, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Myer L; Division of Epidemiology and Biostatistics, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa.; Pokaż więcej
Źródło :: AIDS and behavior [AIDS Behav] 2021 Dec; Vol. 25 (12), pp. 3978-3986. Date of Electronic Publication: 2021 Jun 03.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*
Female ; Humans ; Postpartum Period ; Pregnancy ; South Africa
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 17 17.

Tytuł :: Effect of albumin and CYP2B6 polymorphisms on exposure of efavirenz: A population pharmacokinetic analysis in Chinese HIV-infected adults.
Autorzy :: Meng XM; Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China.
Li ZR; Huashan Hospital, Fudan University, Shanghai 200040, China.
Zheng XY; Huashan Hospital, Fudan University, Shanghai 200040, China.
Liu YX; Huashan Hospital, Fudan University, Shanghai 200040, China.
Niu WJ; Huashan Hospital, Fudan University, Shanghai 200040, China.
Qiu XY; Huashan Hospital, Fudan University, Shanghai 200040, China. Electronic address: .
Lu HZ; Shanghai Public Health Clinical Center, Fudan University, Shanghai 201508, China. Electronic address: .; Pokaż więcej
Źródło :: European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences [Eur J Pharm Sci] 2021 Dec 01; Vol. 167, pp. 105986. Date of Electronic Publication: 2021 Aug 30.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/genetics
Adult ; Albumins ; Alkynes/therapeutic use ; Benzoxazines ; China ; Cyclopropanes ; Cytochrome P-450 CYP2B6/genetics ; Humans ; Polymorphism, Genetic
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 18 18.

Tytuł :: Considerations for the Design of Pre-exposure Prophylaxis (PrEP) Interventions for Women: Lessons Learned from the Implementation of a Novel PrEP Intervention.
Autorzy :: Walters SM; School of Global Public Health, New York University, New York, NY, USA. .
Platt J; Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3300 Kossuth Avenue, Bronx, NY, 10467, USA.
Anakaraonye A; Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3300 Kossuth Avenue, Bronx, NY, 10467, USA.
Golub SA; Department of Psychology, Hunter College, City University of New York, New York, NY, USA.
Cunningham CO; Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3300 Kossuth Avenue, Bronx, NY, 10467, USA.
Norton BL; Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3300 Kossuth Avenue, Bronx, NY, 10467, USA.
Sevelius JM; Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
Blackstock OJ; Division of General Internal Medicine, Department of Medicine, Montefiore Medical Center/Albert Einstein College of Medicine, 3300 Kossuth Avenue, Bronx, NY, 10467, USA.; Pokaż więcej
Źródło :: AIDS and behavior [AIDS Behav] 2021 Dec; Vol. 25 (12), pp. 3987-3999. Date of Electronic Publication: 2021 Jun 17.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pre-Exposure Prophylaxis*
Transgender Persons*
Transsexualism*
Female ; Humans ; Needle-Exchange Programs ; United States
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 19 19.

Tytuł :: Acceptability and Feasibility of Pharmacy-Based Delivery of Pre-Exposure Prophylaxis in Kenya: A Qualitative Study of Client and Provider Perspectives.
Autorzy :: Roche SD; Department of Global Health, University of Washington, 325 Ninth Avenue, Seattle, Washington, 98104, USA. .
Wairimu N; Partners in Health and Research Development, Nairobi, Kenya.
Mogere P; Partners in Health and Research Development, Nairobi, Kenya.
Kamolloh K; Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.
Odoyo J; Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.
Kwena ZA; Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.
Bukusi EA; Department of Global Health, University of Washington, 325 Ninth Avenue, Seattle, Washington, 98104, USA.; Center for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya.; Department of Obstetrics and Gynecology, University of Washington, Seattle, USA.
Ngure K; Partners in Health and Research Development, Nairobi, Kenya.; Department of Community Health, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya.
Baeten JM; Department of Global Health, University of Washington, 325 Ninth Avenue, Seattle, Washington, 98104, USA.; Department of Medicine, University of Washington, Seattle, USA.; Department of Epidemiology, University of Washington, Seattle, USA.
Ortblad KF; Department of Global Health, University of Washington, 325 Ninth Avenue, Seattle, Washington, 98104, USA.; Pokaż więcej
Źródło :: AIDS and behavior [AIDS Behav] 2021 Dec; Vol. 25 (12), pp. 3871-3882. Date of Electronic Publication: 2021 Apr 07.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/therapeutic use
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Pharmacies*
Pharmacy*
Pre-Exposure Prophylaxis*
Feasibility Studies ; Humans ; Kenya
: Czasopismo naukowe

Szczegóły

Skocz do pozycji: 20 20.

Tytuł :: Using Emoji Stickers to Understand End-User Opinions of the Dapivirine Vaginal Ring for HIV Prevention.
Autorzy :: Katz AWK; Women's Global Health Imperative, RTI International, 2150 Shattuck Avenue, Suite 800, Berkeley, CA, 94104, USA. .
Mansoor LE; Centre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Tsidya M; University of North Carolina (UNC) Project-Lilongwe, Lilongwe, Malawi.
Mathebula F; Wits Reproductive Health and HIV Institute (Wits RHI), Johannesburg, South Africa.
Singh D; Magee-Womens Research Institute, Pittsburgh, PA, USA.
Siva S; HIV Prevention Research Unit, South African Medical Research Council (MRC), Durban, South Africa.
Akello C; Makerere University-Johns Hopkins University Research Collaboration, Kampala, Uganda.
Chitowa TH; University of Zimbabwe College of Health Sciences Clinical Trials Research Centre (UZCHS-CTRC), Harare, Zimbabwe.
Garcia M; FHI 360, Durham, NC, USA.
Soto-Torres L; Division of AIDS, NIH, Bethesda, MD, USA.
Montgomery ET; Women's Global Health Imperative, RTI International, 2150 Shattuck Avenue, Suite 800, Berkeley, CA, 94104, USA.; Pokaż więcej
Źródło :: AIDS and behavior [AIDS Behav] 2021 Dec; Vol. 25 (12), pp. 3955-3966. Date of Electronic Publication: 2021 Jun 28.
Typ publikacji :: Journal Article
MeSH Terms :: Anti-HIV Agents*/therapeutic use
Contraceptive Devices, Female*
HIV Infections*/drug therapy
HIV Infections*/prevention & control
Female ; Humans ; Pyrimidines
: Czasopismo naukowe

Szczegóły

Informacja

Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Anti-HIV Agents"" wg kryterium: Temat

Źródło danych

Ogranicz do:

Ogranicz do bazy

Typ dokumentu

Temat

Wydawca

Publikacja

Język